Here's What Key Metrics Tell Us About West Pharmaceutical (WST) Q3 Earnings
West Pharmaceutical Services (WST) reported $747.4 million in revenue for the quarter ended September 2023, representing a year-over-year increase of 8.8%. EPS of $2.16 for the same period compares to $2.03 a year ago.
The reported revenue represents a surprise of +0.07% over the Zacks Consensus Estimate of $746.9 million. With the consensus EPS estimate being $1.86, the EPS surprise was +16.13%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how West Pharmaceutical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Change in Organic Revenue: 5.7% compared to the 7.6% average estimate based on two analysts.
Net Sales- Contract-Manufactured Products: $144.90 million versus the two-analyst average estimate of $136.49 million. The reported number represents a year-over-year change of +20.8%.
Net Sales- Proprietary Products: $602.50 million versus the two-analyst average estimate of $606.24 million. The reported number represents a year-over-year change of +6.3%.
Gross Profit- Proprietary Products: $261.40 million versus the two-analyst average estimate of $254.50 million.
Gross Profit- Contract-Manufactured Products: $26.90 million compared to the $20.49 million average estimate based on two analysts.
View all Key Company Metrics for West Pharmaceutical here>>>
Shares of West Pharmaceutical have returned -4.6% over the past month versus the Zacks S&P 500 composite's -3.4% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report
